Re-stenosis After Drug-eluting Stents in Cardiac Allograft Vasculopathy

Journal of Heart and Lung Transplantation

Volumn 27, Issue 6, 2008, Pages 610-615

  Aqel, Raed A ^a   Wells, Bryan J ^b   Hage, Fadi G ^a   Tallaj, Jose ^a   Benza, Raymond ^a   Pamboukian, Salpy ^a   Rayburn, Barry ^a   McGiffin, David ^c   Kirklin, James ^c   Bourge, Robert ^a  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CLINICAL ARTICLE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; KAPLAN MEIER METHOD; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 43949090486     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.02.010     Document Type: Article

References (30)

1. Redonnet M., Tron C., Koning R., et al. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. Transplant Proc 32 (2000) 463-465
2. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 (2007) 769-781
3. Young J.B. Allograft vasculopathy: diagnosing the nemesis of heart transplantation. Circulation 100 (1999) 458-460
4. Hosenpud J.D., Shipley G.D., and Wagner C.R. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant 11 (1992) 9-23
5. Mehra M.R., Uber P.A., Ventura H.O., Scott R.L., and Park M.H. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 43 (2004) 806-810
6. Mehra M.R., Ventura H.O., Stapleton D.D., et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 14 (1995) 632-639
7. Kemna M.S., Valantine H.A., Hunt S.A., et al. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 128 (1994) 68-72
8. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
9. Srivastava R., Keck B.M., Bennett L.E., and Hosenpud J.D. The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation 70 (2000) 606-612
10. Halle III A.A., DiSciascio G., Massin E.K., et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 26 (1995) 120-128
11. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
12. Gustafsson F., and Ross H.J. Proliferation signal inhibitors in cardiac transplantation. Curr Opin Cardiol 22 (2007) 111-116
13. Bader F.M., Kfoury A.G., Gilbert E.M., et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 298-301
14. Tanaka K., Li H., Curran P.J., et al. Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol 97 (2006) 1192-1197
15. Doshi A.A., Rogers J., Kern M.J., and Hauptman P.J. Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. Am J Cardiol 93 (2004) 90-92
16. Benza R.L., Zoghbi G.J., Tallaj J., et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol 43 (2004) 1973-1981
17. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
18. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 17 (1998) 744-753
19. Yeung A.C., Davis S.F., Hauptman P.J., et al. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant 14 suppl (1995) S215-S220
20. Paul L.C. Calcium channel blockers and angiotensin-converting enzyme inhibitors in the prevention of graft vasculopathy. J Heart Lung Transplant 19 (2000) 409-413
21. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 96 (1997) 1398-1402
22. Mehra M.R., Ventura H.O., Chambers R.B., et al. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. J Heart Lung Transplant 16 (1997) 743-751
23. Kobashigawa J.A., and Patel J.K. Immunosuppression for heart transplantation: where are we now?. Nat Clin Pract Cardiovasc Med 3 (2006) 203-212
24. Schnetzler B., Drobinski G., Dorent R., et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 19 (2000) 557-565
25. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
26. Hognestad A., Endresen K., Wergeland R., et al. Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 24 (2005) 1026-1032
27. Ruygrok P.N., Farb A., Coverdale H.A., Gibbs H.C., and Virmani R. Histology of in-stent restenosis in a transplanted heart. J Heart Lung Transplant 23 (2004) 143-146
28. Aqel R., Gupta R., Tallaj J.A., and Zoghbi G.J. Re-stenosis of a sirolimus-coated stent in a heart transplant recipient with allograft vasculopathy. J Heart Lung Transplant 24 (2005) 1444
29. Simpson L., Lee E.K., Hott B.J., Vega D.J., and Book W.M. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant 24 (2005) 1211-1217
30. Hoye A., Tanabe K., Lemos P.A., et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 43 (2004) 1954-1958